AAA
VKTX icon

Affinity Asset Advisors’s Viking Therapeutics VKTX Stock Holding History

Affinity Asset Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-250,000
Closed -$2.35M – 86
2022
Q4 		$2.35M Buy
+250,000
New +$1.12M 0.92% 34

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Affinity Asset Advisors's VKTX Position: Q2 2025 in Review

Affinity Asset Advisors sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 25,000 shares — an estimated $604K sold.

Affinity Asset Advisors first reported a position in VKTX in Q3 2022 and held it in 8 quarters. The position peaked at $10.4M in Q1 2023. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Affinity Asset Advisors reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 25,000 Viking Therapeutics shares in Q2 2025, an estimated $604K.
  • Affinity Asset Advisors first reported a position in Viking Therapeutics in Q3 2022 and held it in 8 quarters.
  • Affinity Asset Advisors's Viking Therapeutics position peaked at $10.4M in Q1 2023.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.